<h3>
	<img align="left" alt="" src="http://i.imgur.com/BATqkk6.jpg" style="width: 20%; float: left;" /> <strong>Buzz: Deep job cuts looming at GlaxoSmithKline</strong></h3>
<p>With sales of its flagship product Advair slipping as its new respiratory drugs fail to gain rapid traction, Big Pharma player GlaxoSmithKline is prepping some deep cuts in its U.S. operations, according to several reports over the holiday weekend. <a href="http://www.fiercebiotech.com/story/buzz-deep-job-cuts-looming-glaxosmithklines-us-ops-rtp-philly/2014-12-01"><strong>Read more</strong></a>&nbsp;| <a href="http://www.fiercebiotech.com/offer/signup"><strong>Subscribe to&nbsp;<em>FierceBiotech</em></strong></a></p>
<p>The current reduction plan comes on top of a &pound;1 billion reduction program announced early in 2013. Those cuts were mainly to come from manufacturing and R&amp;D, with job cuts targeted in Europe. <strong><a href="http://www.fiercepharma.com/story/gsk-ready-ax-hundreds-us-sources-tell-bloomberg/2014-12-01">Read more</a> | <a href="http://www.fiercepharma.com/offer/signup">Subscribe to <em>FiercePharma</em></a></strong></p>
<h3>
	<img align="left" src="http://i.imgur.com/wpC6Bfo.jpg" width="20%" /><strong>FDA approves J&amp;J&#39;s insulin pump, continuous glucose monitor combo device</strong></h3>
<p>The FDA has approved the Animas Vibe, a combination insulin pump and continuous glucose monitor (CGM). It allows patients with Type 1 diabetes to monitor blood glucose levels mostly without a finger stick and adjust insulin delivery based on that data. Animas is a Johnson &amp; Johnson company. <strong><a href="http://www.fiercemedicaldevices.com/story/fda-approves-animas-insulin-pump-continuous-glucose-monitor-combo-device/2014-12-01">Read more</a> | <a href="http://www.fiercemedicaldevices.com/offer/signup">Subscribe to <em>FierceMedicalDevices</em></a></strong></p>
<h3>
	<img align="left" src="http://media.glassdoor.com/m/107/bristol-myers-squibb-office.jpg" width="20%" /><strong>Bristol-Myers cutting up to 1,000 jobs in China</strong></h3>
<p>Western drugmakers were pretty head-over-heels about prospects in China until authorities launched a bribery probe against GlaxoSmithKline which dragged on for a year and ended with a half billion dollar fine and people going to jail. That has left drugmakers to rethink their strategies there and for Bristol-Myers Squibb &nbsp;it means cutting hundreds off its payroll.&nbsp;Chinese media said most of the cuts are sales reps. A BMS spokesperson in an email today declined to give specific numbers or details of the cuts. <a href="http://www.fiercepharma.com/story/bms-makes-cuts-china-reports-say-1000/2014-12-02"><strong>Read more</strong></a> |&nbsp;<strong><a href="http://www.fiercepharma.com/offer/signup">Subscribe to&nbsp;<em>FiercePharma</em></a></strong></p>
<p><strong>Marketing: </strong>Phase III failure dashes Novartis&#39; hopes of Gilenya label expansion. <a href="http://www.fiercepharmamarketing.com/story/phiii-failure-dashes-novartis-hopes-gilenya-label-expansion/2014-12-02">Read more</a> | <a href="http://www.fiercepharmamarketing.com/offer/signup">Subscribe to <em>FiercePharmaMarketing</em></a></p>
<p><strong>Animal health: </strong>Zoetis R&amp;D chief Catherine Knupp on innovation and the fight to stay atop animal health. <a href="http://www.fierceanimalhealth.com/story/zoetis-rd-chief-catherine-knupp-innovation-and-fight-stay-atop-animal-healt/2014-12-01">Read more</a> | <a href="http://www.fierceanimalhealth.com/offer/signup">Subscribe to <em>FierceAnimalHealth</em></a></p>
<p><strong>Research: </strong>Harvard, MIT teams identify a &#39;pre-malignant&#39; phase for blood cancers. <a href="http://www.fiercebiotechresearch.com/story/harvard-mit-teams-identify-pre-malignant-phase-blood-cancers/2014-12-02">Read more</a> | <a href="http://www.fiercebiotechresearch.com/offer/signup">Subscribe to <em>FierceBiotechResearch</em></a></p>
<p><strong>Diagnostics: </strong>Germany&#39;s nanoPET partners with Boehringer Ingelheim for imaging Dx deal. <a href="http://www.fiercediagnostics.com/story/germanys-nanopet-partners-boehringer-ingelheim-imaging-dx-deal/2014-12-01">Read more</a> | <a href="http://www.fiercediagnostics.com/offer/signup">Subscribe to <em>FierceDiagnostics</em></a></p>
<p><strong>Manufacturing: </strong>Italy clears Novartis vaccine manufacturing in deaths following vaccinations. <a href="http://www.fiercepharmamanufacturing.com/story/italy-clears-novartis-vacccine-manufacturing-deaths-following-vaccinations/2014-12-01">Read more</a> | <a href="http://www.fiercepharmamanufacturing.com/offer/signup">Subscribe to <em>FiercePharmaManufacturing</em></a></p>
<p><strong>IT: </strong>Nvidia backs projects to tap GPUs for cancer research. <a href="http://www.fiercebiotechit.com/story/nvidia-backs-projects-tap-gpus-cancer-research/2014-12-01">Read more</a> | <a href="http://www.fiercebiotechit.com/offer/signup">Subscribe to <em>FierceBiotechIT</em></a></p>
<p><strong>Vaccines: </strong>GSK, NIH gear up for Ebola vaccine trial expansion after success in Phase I. <a href="http://www.fiercevaccines.com/story/gsk-nih-gear-ebola-vaccine-trial-expansion-after-success-phi/2014-12-02">Read more</a> | <a href="http://www.fiercevaccines.com/offer/signup">Subscribe to <em>FierceVaccines</em></a></p>
<p><strong>CRO: </strong>Almac partners up to keep patients--and data--safe in trial emergencies.<strong>&nbsp;</strong><a href="http://www.fiercecro.com/story/almac-partners-keep-patients-and-data-safe-trial-emergencies/2014-12-01">Read more</a>&nbsp;| <a href="http://www.fiercecro.com/offer/signup">Subscribe to <em>FierceCRO</em></a></p>
<p><strong>Drug delivery: </strong>U.S. Army deploys a novel topical antiseptic to fight ebolavirus. <a href="http://www.fiercedrugdelivery.com/story/us-army-deploys-novel-topical-antiseptic-fight-ebolavirus/2014-12-03">Read more</a> | <a href="http://www.fiercedrugdelivery.com/offer/signup">Subscribe to <em>FierceDrugDelivery</em></a></p>
